| Literature DB >> 27132576 |
Samuel J Ohlander1, Mark C Lindgren1, Larry I Lipshultz2.
Abstract
Hypogonadism and its therapies have a significant impact on male fertility potential. It is necessary to determine the etiology to treat and counsel the patient appropriately on therapeutic options. For the hypogonadal male on exogenous testosterone, management should begin with cessation of the exogenous testosterone and supplemental subcutaneous human chorionic gonadotropin and an oral follicle-stimulating hormone (FSH)-inducing agent to allow reestablishment of the hypothalamic-pituitary-gonadal axis and spermatogenesis. Further supplemental therapy with recombinant FSH in some patients may be necessary to achieve optimal semen parameters.Entities:
Keywords: Exogenous; Hypogonadism; Hypogonadotropic; Infertility; Spermatogenesis; Testosterone
Mesh:
Substances:
Year: 2016 PMID: 27132576 DOI: 10.1016/j.ucl.2016.01.006
Source DB: PubMed Journal: Urol Clin North Am ISSN: 0094-0143 Impact factor: 2.241